

LA JOLLA PHARMACEUTICAL CO

Form 8-K

May 11, 2004

**Table of Contents**

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549**

---

**FORM 8-K**

**CURRENT REPORT  
PURSUANT TO SECTION 13 or 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): May 10, 2004

**La Jolla Pharmaceutical Company**

---

(Exact Name of Registrant as Specified in Charter)

Delaware

---

0-24274

---

33-0361285

---

(State or Other Jurisdiction  
of Incorporation)

(Commission  
File Number)

(IRS Employer  
Identification No.)

6455 Nancy Ridge Drive, San Diego, California

---

92121

---

(Address of Principal Executive Offices)

(Zip Code)

Registrant's telephone number, including area code:

(858)  
452-6600

---

N/A

---

(Former Name or Former Address, if Changed Since Last Report)

---

---

---

**TABLE OF CONTENTS**

Item 5. Other Events and Required FD Disclosure.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

SIGNATURES

EXHIBIT INDEX

EXHIBIT 99.1

---

**Table of Contents**

**Item 5. Other Events and Required FD Disclosure.**

On May 10, 2004, the Company issued a press release announcing that it would give four presentations on previously released data on Riquent® (abetimus sodium), its drug candidate for the treatment of lupus renal disease, at the 7th International Congress on Systemic Lupus Erythematosus (SLE) and Related Conditions. The conference takes place May 10-13, 2004. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.**

(c) *Exhibits.* The following exhibits are filed with this report on Form 8-K:

| <b>Exhibit<br/>Number</b> | <b>Description of Exhibit</b> |
|---------------------------|-------------------------------|
| 99.1                      | Press Release                 |

---

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**La Jolla Pharmaceutical Company**

Date: May 11, 2004

By: /s/ Gail A. Sloan

---

Gail A. Sloan  
Vice President of Finance and Controller

---

**Table of Contents**

**EXHIBIT INDEX**

**Exhibit  
Number**

**Description of Exhibit**

---

99.1 Press Release